Investtechs modelporteføljer faldt i tredje kvartal gennemsnitligt 5.7 procentpoint i forhold til referenceindeks.
Marked | Merafk. Q1* | Merafk. Q2* | Merafk. Q3* | Merafk. Q4* | Merafk. 2007 |
Stockholm | -6.3% | +11.0% | -5.0% | -0.4% | |
Helsingfors | -1.0% | +7.5% | -7.9% | -1.5% | |
Amsterdam | +0.7% | +12.5% | -2.6% | +10.6% | |
København | -1.1% | +3.6% | -6.3% | -3.8% | |
Oslo | +1.5% | +6.9% | -6.0% | +2.4% | |
London | +2.6% | 0.0% | -7.2% | -4.7% | |
Frankfurt/CDAX | +3.6% | -17.3% | -3.8% | -17.5% | |
Nasdaq | +7.9% | -5.8% | -6.4% | -4.3% | |
Snit | +1.0% | +2.3% | -5.7% | -2.4% |
I hele perioden er der lagt vægt på, at aktierne i porteføljerne skulle genspejle markedssammensætningen, og risikoen i porteføljerne har været på linje med markedet. Vi tror, at det svage resultat i sidste kvartal først og fremmest skyldes statistiske tilfældigheder. Det kan også i nogen grad skyldes, at markedet totalt set har været negativt (eller sidelæns) i perioden, da købesignaler (som ofte er grundlaget for at en aktie kommer med i porteføljen) i sådanne situationer sjældnere slår til.
Strategien fra tidligere anses fortsat god:
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.